Meeting Confirms Bioinformatics Status As Key Technology for Pharmaceutical Cos.
LONDON--"Bioinformatics has moved from high potential to key operational technology," remarked Dominic Clark of Glaxo Wellcome at the start of a conference he chaired here February 15-16. (Sun, 07 Feb 2010 17:05:29 GMT)

CDC to Fund Genomics Knowledge Center
NEW YORK (GenomeWeb News) – The Office of Public Health Genomics at the US Centers for Disease Control and Prevention will grant $1.5 million to fund the creation of a center that will help plan and develop systematic evidence reviews on genomics applications, among other efforts. (Mon, 08 Feb 2010 20:50:09 GMT)

QIAGEN Acquires Exclusive Licence for Key PI3K gene
VENLO, The Netherlands, February 8 /PRNewswire-FirstCall/ -- QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint PCR assays. (Tue, 09 Feb 2010 01:14:42 GMT)

An Early Warning System for Cancer
Autoantibodies could alert doctors to cancer development. A new screening tool developed by scientists in Denmark may help detect the earliest stages of cancer by taking advantage of the body's own defenses. The researchers constructed a microarray system that analyzes patients' blood for a specific class of immune agents called autoantibodies. These are agents that attack the body's own tissue ... (Tue, 09 Feb 2010 05:19:15 GMT)

Research and Markets: Bioinformatics for Glycobiology and Glycomics: an Introduction
DUBLIN----Research and Markets has announced the addition of John Wiley and Sons Ltd's new report "Bioinformatics for Glycobiology and Glycomics: An Introduction" to their offering. (Thu, 04 Feb 2010 13:54:00 GMT)

DNAVision Adds Illumina HiSeq to Service Offerings
NEW YORK (GenomeWeb News) – DNAVision, a Belgian genomics services provider, today said that it has purchased one of Illumina's new sequencing instruments, the HiSeq 2000, for its service offerings. (Mon, 08 Feb 2010 20:50:18 GMT)

QIAGEN Acquires Exclusive Licence for Key PI3K gene
VENLO, The Netherlands, February 8 /PRNewswire/ -- - Patent Licensed From Johns Hopkins University for PCR-based Companion Diagnostics for Cancer Treatments QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint ... (Mon, 08 Feb 2010 21:11:41 GMT)

Munich Startup Nanotype Forces Its Way into Microarray Market with C-FIT Technology
Finding the right partner is not only a problem that haunts many startup companies. It also may be a major challenge for probe and target molecules on microarrays. (Mon, 08 Feb 2010 17:05:12 GMT)